PurposeSoma Targeted, High photocurrent, low-light sensitive channelrhodopsin (ChRger2) for optogenetic activation with systemic delivery or for low-light activation. Driven by the CamKIIa promoter.
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||129393||Standard format: Plasmid sent in bacteria as agar stab||1||$75|
This material is available to academics and nonprofits only.
Vector backbonepAAV CaMKIIa WPRE pA
- Backbone size w/o insert (bp) 5076
- Total vector size (bp) 7125
Vector typeMammalian Expression, AAV
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Growth Strain(s)NEB Stable
Copy numberHigh Copy
Gene/Insert namesoma targeted ChRger2
Insert Size (bp)2049
- Promoter CaMKIIa
/ Fusion Protein
- Kv2.1-TS-EYFP (C terminal on insert)
- Cloning method Ligation Independent Cloning
- 5′ sequencing primer GcttcgttacGCCgagtgg
- 3′ sequencing primer CATAGCGTAAAAGGAGCAACA (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
Addgene NGS results detect a mixed population at base 2849 (T/G), which could result in a D21Y variant in EYFP. This construct fluoresces as expected.
Depositor has evidence that soma-targeted constructs may have different optical properties from their parent ChRgers and they have not been fully characterized. Users should be aware that they are beta-testing.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pAAV-CaMKII-STChRger2-TS-EYFP was a gift from Viviana Gradinaru (Addgene plasmid # 129393 ; http://n2t.net/addgene:129393 ; RRID:Addgene_129393)
For your References section:Machine learning-guided channelrhodopsin engineering enables minimally invasive optogenetics. Bedbrook CN, Yang KK, Robinson JE, Mackey ED, Gradinaru V, Arnold FH. Nat Methods. 2019 Oct 14. pii: 10.1038/s41592-019-0583-8. doi: 10.1038/s41592-019-0583-8. 10.1038/s41592-019-0583-8 PubMed 31611694